Akèy › Karsinòm Nèwo-endokrin › Missouri
Etid klinik pou Karsinòm Nèwo-endokrin nan Missouri
3 etid pou Karsinòm Nèwo-endokrin ap chèche patisipan nan sit nan Missouri.
Vil nan Missouri
Tèks ofisyèl etid la (Anglè)
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- Washington University Medicine, St Louis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07488923A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Washington University School of Medicine (Siteman Cancer Center), St Louis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT05652686A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Washington University Infusion Center Pharmacy, St Louis
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT03093116Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.